Compare · BDX vs IINN
BDX vs IINN
Side-by-side comparison of Becton Dickinson and Company (BDX) and Inspira Technologies Oxy B.H.N. Ltd. (IINN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and IINN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.45B, about 3083.0x IINN ($16.7M).
- IINN has been more active in the news (12 items in the past 4 weeks vs 9 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 2 for IINN).
- Company
- Becton Dickinson and Company
- Inspira Technologies Oxy B.H.N. Ltd.
- Price
- $191.21-1.34%
- $0.38+0.51%
- Market cap
- $51.45B
- $16.7M
- 1M return
- -
- -34.36%
- 1Y return
- -
- -66.56%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 12
- Recent ratings
- 25
- 2
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest IINN
- SEC Form 4 filed by Inspira Technologies Oxy B.H.N. Ltd.
- Correction: QTREX Quantum Announces Clean Capital Structure
- QTREX Quantum Announces Clean Capital Structure
- SEC Form 4 filed by Inspira Technologies Oxy B.H.N. Ltd.
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- SEC Form 4 filed by Inspira Technologies Oxy B.H.N. Ltd.
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX Interconnect Independently Tested at 20 mK by a Leading Quantum Computing Company; Over 100 dB Channel Isolation, 60 dB Beyond the Market Leader
- Chief Executive Officer Ben-Noon Dagi Shahar bought $119,543 worth of Ordinary Shares (168,894 units at $0.71), increasing direct ownership by 5% to 3,646,133 units (SEC Form 4)
- Amendment: Chief Executive Officer Ben-Noon Dagi Shahar was granted 550,000 units of Ordinary Shares, increasing direct ownership by 19% to 3,477,239 units (SEC Form 4)